Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jesus Rame

Advanced Heart Failure and Transplant Cardiology Philadelphia, PA Medical Doctor

NPI 1417914953 CMS profile 18567

925 Chestnut Street, Mezzanine, Philadelphia, PA 19107

Open in the dashboard

General payments

$335,563

635 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$41,263 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Jesus Rame of Philadelphia, PA is reported in the CMS Open Payments database as having received $335,563 across 635 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $41,263 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64,593 117
2024 General $42,648 102
2023 General $93,777 142
2022 General $109,199 153
2021 General $4,176 50
2020 General $10,098 41
2019 General $11,071 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesus Rame
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Jesus Rame were reported at $64,593. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Jesus Rame Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $11,071 $863 $224–$4,562 $163
2020 $10,098 $452 $122–$3,992 $114
2021 $4,176 $550 $159–$3,571 $132
2022 $109,199 $729 $221–$4,357 $149
2023 $93,777 $1,002 $309–$5,827 $160
2024 $42,648 $931 $273–$5,204 $164
2025 $64,593 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $142,520 112 payments
  2. E.R. Squibb & Sons, L.L.C. $84,394 91 payments
  3. Lexicon Pharmaceuticals, Inc. $42,491 32 payments
  4. Abbott Laboratories $35,754 130 payments
  5. Fresenius USA Marketing, Inc. $10,750 16 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $6,904 7 payments
  7. Abiomed $1,873 27 payments
  8. Medtronic, Inc. $1,846 2 payments
  9. Actelion Pharmaceuticals US, Inc. $1,265 36 payments
  10. Impulse Dynamics (USA) Inc. $869 13 payments
  11. Other $6,896 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $161,549 40 payments
  2. Travel and Lodging $53,825 117 payments
  3. Consulting Fee $43,594 19 payments
  4. Honoraria $38,880 9 payments
  5. Food and Beverage $21,002 434 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $15,956 7 payments
  7. Education $756 9 payments
Products named General payments · program years 2019–2025
  1. VERQUVO Cardiovascular $123,866 105 payments
  2. VERQUVO Cardiovascular $59,592 51 payments
  3. CAMZYOS $57,252 60 payments
  4. Inpefa $42,491 32 payments
  5. FreeStyle Libre Pro $14,080 11 payments
  6. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $9,501 51 payments
  7. Kerendia $6,886 6 payments
  8. HeartMate 3 Left Ventricular Dev $6,757 16 payments
  9. CARDIOMEMS $2,319 10 payments
  10. HeartWare HVAD $1,800 1 payment
  11. Other $14,543 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,452

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$2,117,928

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

40.6%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 98 $820,930
Uptravi Selexipag Brand 15 $410,377
Tyvaso Dpi Treprostinil Brand 14 $336,828
Opsumit Macitentan Brand 14 $178,958
Jardiance Empagliflozin Brand 122 $117,008
Entresto Sacubitril/Valsartan Brand 102 $104,322
Farxiga Dapagliflozin Propanediol Brand 71 $67,795
Eliquis Apixaban Brand 63 $42,512
Tacrolimus Generic 32 $9,023
Dapagliflozin Dapagliflozin Propanediol Brand 14 $6,604

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$55,135

Medicare's payments for the services billed

Medicare patients

217

Average age 70

Services billed

781

83 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 72%
Chronic kidney disease 59%
Ischemic heart disease 58%
Atrial fibrillation 50%
Diabetes 47%
Arthritis 43%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Inpefa
  • Lexicon Pharmaceuticals, Inc. $24,584
$24,584 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $15,566
$15,566 98 —
TYVASO
  • United Therapeutics Corporation $97
$97 14 —
XARELTO
  • Janssen Pharmaceuticals, Inc $56
$56 — —
REMODULIN
  • United Therapeutics Corporation $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

635 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record